Disopyramid phosphate Chemical Properties

Melting point:

202-204°C

storage temp. 

2-8°C

solubility 

DMSO (Slightly, Heated, Sonicated), Methanol (Slightly), Water (Slightly)

color 

White to Off-White

Safety Information

Hazard Codes 

Xn

Risk Statements 

22

Safety Statements 

36

WGK Germany 

3

RTECS 

UR8440000

HS Code 

2933399090

MSDS

• Language:English Provider:SigmaAldrich

Disopyramid phosphate Usage And Synthesis

Originator

Rythmodan,Cassenne,France,1969

Uses

Disopyramide Phosphate is an antiarrhythmic (class IA). Sodium channel blocker.

Uses

Disopyramide phosphate salt has been used as an internal standard for plasma sample analysis by mass spectrometry. It might be used as a test compound in a teratogenicity study.

Uses

Cardiac depressant (anti-arrhythmic).

Definition

ChEBI: Disopyramide phosphate is an organoammonium phosphate. It is functionally related to a disopyramide.

Manufacturing Process

To a solution of 35.3 parts of phenylacetonitrile and 47.6 parts of 2- bromopyridine in 175 parts of dry toluene is added 53.4 parts of sodamide slowly with stirring over a period of 45 minutes. The resultant mixture is stirred at 100°C for 2 hours before it is cooled and the excess sodamide is decomposed by the addition of water. The toluene layer is separated and washed with water to remove excess alkali. The toluene solution is extracted with 6 N hydrochloric acid and the acid extract is made alkaline and then extracted with toluene. The toluene solution is dried over sodium sulfate and the solvent is evaporated. Recrystallization of the residue from alcohol-hexane gives α-phenyl-2-pyridineacetonitrile melting at about 87-88°C.
To a solution of 41 parts of α-phenyl-2-pyridineacetonitrile in 350 parts of dry toluene is added 9.2 parts of sodamide and the mixture is stirred and heated at 90°C for 30 minutes. Heating is stopped and a solution of 38.5 parts of 2- diisopropylaminoethyl chloride in 110 parts of dry toluene is added slowly over a period of 30 minutes. The mixture is stirred and refluxed for 6 hours before it is cooled and decomposed by the addition of water. The toluene layer is separated and washed with water and extracted with 6 N hydrochloric acid. The acid extract is made alkaline and extracted with toluene. The toluene solution is washed with water and dried and the solvent is evaporated. Distillation of the residue gives 4-diisopropylamino-2-phenyl-2-(2-pyridyl)- butyronitrile boiling at about 145°-160°C at 0.3 mm pressure.
A solution of 27.2 parts of 4-diisopropylamino-2-phenyl-2-(2- pyridyl)butyronitrile in 200 parts of concentrated sulfuric acid is heated on a steam bath for 4 hours and then poured onto ice. The resultant mixture is alkalized with 10 N sodium hydroxide, and the pH is adjusted to 6 by the addition of acetic acid. The solution is washed once with benzene before it is alkalized again with 10 N sodium hydroxide solution. The resultant mixture is extracted with benzene, and the solvent is evaporated from the benzene extract. The resultant residue is dissolved in ethanol and the alcohol solution is treated with charcoal and filtered. Evaporation of the solvent leaves a residue which is recrystallized from hexane to give 4-diisopropylamino-2- phenyl-2-(2-pyridyl)butyramide melting at about 94.5-95°C. It may be converted to the phosphate with phosphoric acid.

brand name

Norpace (Searle).

Therapeutic Function

Antiarrhythmic

General Description

Disopyramide phosphate, -[2(diisopropylamino)ethyl]- -phenyl-2-pyridineacetamidephosphate (Norpace), is an oral and intravenousclass IA antiarrhythmic agent. It is quite similar to quinidineand procainamide in its electrophysiological properties, inthat it decreases phase 4 diastolic depolarization, decreasesconduction velocity, and has vagolytic properties.31 It is usedclinically in the treatment of refractory, life-threatening ventriculartachyarrhythmias. Oral administration of the drugproduces peak plasma levels within 2 hours. The drug isbound approximately 50% to plasma protein and has a halflifeof 6.7 hours in humans. More than 50% is excretedunchanged in the urine. Therefore, patients with renal insufficiencyshould be monitored carefully for evidence ofoverdose. Disopyramide phosphate commonly exhibits sideeffects of dry mouth, constipation, urinary retention, andother cholinergic blocking actions because of its structuralsimilarity to anticholinergic drugs.

Biochem/physiol Actions

Class IA antiarrhythmic; sodium channel blocker

Disopyramid phosphate (22059-60-5)Related Product Information

• DISOPYRAMIDE
• 4'-CHLOROACETANILIDE
• Triethyl phosphate
• Sodium polyphosphate
• Zinc phosphate
• N,N-Dimethylacetamide
• AMPHISOL A
• DICALCIUM PHOSPHATE DIHYDRATE
• Acetaminophen
• Pyridinium chlorochromate
• Acetamide
• Pentasodium triphosphate hexhydrate
• Tylosin phosphate
• Thioacetamide
• Ammonium phosphate dibasic
• ADENOSINE 5'-TRIPHOSPHATASE
• Alkaline Phosphatase
• Trisodium phosphate